EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study

Jinxin Liu iD, Xinxiu Shi, Yankun Shao iD

Brain and Behavior · 2024

DOI: 10.1002/brb3.3624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2024. Verfasst von Jinxin Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Sodium-Glucose Transporter 2 Inhibitors, Polymorphism, Single Nucleotide, Neurodegenerative Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aims to evaluate the effects of sodium‐glucose cotransporter 1 inhibitors (SGLT1i) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) on neurodegenerative disorders and to investigate the role of hemoglobin A1c (HbA1c) levels.

Methods

Utilizing drug target Mendelian randomization, we employed single nucleotide polymorphisms (SNPs) proximal to the SLC5A1 and SLC5A2 genes to analyze the influence of SGLT1i and SGLT2i on Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), frontotemporal dementia (FTD), Lewy body dementia (LBD), and amyotrophic lateral sclerosis (ALS), with type 2 diabetes (T2D) as a positive control. An additional analysis examined the impact of HbA1c levels on the same disorders.

Results

SGLT1i exhibited a significant association with decreased risk for ALS and MS. Conversely, SGLT2i were linked to an increased risk of AD, PD, and MS. Elevated HbA1c levels, independent of SGLT1 and SGLT2 effects, were associated with an increased risk of PD. Sensitivity analyses supported the robustness of these findings.

Conclusion

Our study suggests that SGLT1i may confer protection against ALS and MS, whereas SGLT2i could elevate the risk of AD, PD, and MS. Additionally, elevated HbA1c levels emerged as a risk factor for PD. These findings underscore the importance of personalized approaches in the utilization of SGLT inhibitors, considering their varying impacts on the risks of neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mendelian Randomization AnalysisSodium-Glucose Transporter 2 InhibitorsPolymorphism, Single NucleotideNeurodegenerative DiseasesGlycated HemoglobinSodium-Glucose Transporter 1HumansDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2Parkinson DiseaseAmyotrophic Lateral SclerosisAlzheimer DiseaseMultiple Sclerosis

Stichwörter der Autor:innen

Mendelian randomizationdrug targethemoglobin A1cneurodegenerative disorderssodium‐glucose cotransporter

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinSodium-Glucose Transporter 1Sodium-Glucose Transporter 2SLC5A1 protein, humanSLC5A2 protein, humanhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China.

ORCID-Profile: Jinxin Liu, Yankun Shao

Zitieren

APA

Liu, J., Shi, X., & Shao, Y. (2024). Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study. Brain and Behavior. https://doi.org/10.1002/brb3.3624

Vancouver

Liu J, Shi X, Shao Y. Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study. Brain and Behavior. 2024. doi:10.1002/brb3.3624

BibTeX
@article{Liu2024,
  author = {Liu, Jinxin and Shi, Xinxiu and Shao, Yankun},
  title = {Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study},
  journal = {Brain and Behavior},
  year = {2024},
  doi = {10.1002/brb3.3624}
}
Kostenlos starten →